Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis

Table 3 Prognostic factors of breast cancer brain metastasis

Item	Univariate Cox		Multivariate Cox
	HR (95%CI)	P	HR (95%CI)	P
Age at diagnosis of BM (yr)
≤ 35	Reference
> 35	1.033 (0.315-3.385)	0.957
Time from BC to BM (mo)
≤ 24	Reference
> 24	0.896 (0.482-1.664)	0.727
Menstrual status at diagnosis of BM
Premenopause	Reference
Menopause	0.685 (0.331-1.416)	0.307
Molecular type
Luminal A type	0.253 (0.087-0.730)	0.011	0.227 (0.074-0.693)	0.009
Luminal B type	0.279 (0.128-0.607)	0.001	0.293 (0.129-0.663)	0.003
HER2-overexpressing type	0.274 (0.121-0.618)	0.002	0.319 (0.135-0.754)	0.009
Triple-negative type	Reference
Bone metastasis
No	Reference
Yes	1.980 (1.135-3.453)	0.016	2.011 (1.056-3.831)	0.034
Liver metastasis
No	Reference
Yes	1.121 (0.626-2.007)	0.701
Lung metastasis
No	Reference
Yes	1.616 (0.929-2.810)	0.089
Number of liver, lung and bone metastases
≤ 2	Reference
> 2	1.548 (0.894-2.682)	0.119
Number of metastases to other sites
< 2	Reference
≥ 2	1.425 (0.711-2.858)	0.318
Tumor stage
I-II	Reference
III-IV	0.813 (0.466-1.419)	0.466
Lymph node stage
N0-N1	Reference
N2-N3	0.843 (0.486-1.464)	0.545
Pathological type
Others	0.287 (0.073-1.133)	0.075
Invasive lobular carcinoma	Reference
Invasive ductal carcinoma	0.208 (0.060-0.725)	0.014	NS
Symptoms
No	Reference
Yes	2.171 (1.191-3.959)	0.011	1.923 (1.005-3.680)	0.048
Size of BM (cm)
≤ 3	Reference
> 3	0.803 (0.449-1.439)	0.462
Number of BM
≤ 3	Reference
> 3	1.248 (0.721-2.160)	0.428
Surgery for BM
No	Reference
Yes	0.744 (0.348-1.591)	0.446
Treatment after BM
Local therapy	Reference
Medication alone	1.531 (0.638-3.674)	0.064
Systemic therapy	0.748 (0.317-1.765)	0.507
Local therapy
SRT	1.350 (0.513-3.549)	0.543
WBRT	1.600 (0.633-4.043)	0.320
Both	1.935 (0.680-5.506)	0.216
Neither	Reference

95%CI: 95% confidence interval; NS: Not statistically significant; HR: Hazard ratio; BC: Breast Cancer; BM：Brain Metastasis; WBRT: Whole brain radiation therapy; SRT: Stereotactic radiotherapy; HER2: Human epidermal growth factor receptor 2.